LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)

N.Y Ngoi,J-Y Lee,Y.W Lim,D Lim,Y.L Thian,A Gopinathan,S.E Lim,J Low,J Ng,P Tong,J Zhu,B.C Tai,Y.J Lee,J Park,J-W Kim,B-G Kim,D.S Tan

doi:10.1016/j.annonc.2023.10.406

LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)

N.Y Ngoi, J-Y Lee + Show 15 more

https://doi.org/10.1016/j.annonc.2023.10.406

Copy DOI

Export

Save

Cite

Journal: Annals of Oncology

Publication Date: Nov 1, 2023

Affiliation: National University Cancer Institute, Singapore, Yonsei University, National University Hospital, Seoul National University Hospital, Sungkyunkwan University

#Recurrent Gynecological Cancer #Recurrent Cancer #Recurrent Clear Cell #Efficacy Of Pembrolizumab #Preliminary Efficacy #Gynecological Cancer #Clear Cell

Abstract
Full-Text
Similar Papers

Abstract

Listen

LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)